Purdue Pharma's business development director and head of medical affairs talk to Scrip about the company's hunt for new drugs to add to its portfolio outside of the opioid pain therapy space and how it is preparing for generic erosion and increasing pricing pressures in the US.
Purdue Pharma LP hinted on the sidelines of the BIO-Europe partnering conference earlier this month that a significant acquisition announcement will be made before the end of 2016, which will see the company expand its R&D to a new therapy area outside of opioid pain treatments.
Kathryn Gregory, executive director of licensing and business development at Purdue, told Scrip that the company is looking for the...
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
